葛兰素史克-话题@MedSci

#葛兰素史克#

69篇内容 | 2635人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1315765, encodeId=40551315e65e8, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请, objectType=article, longId=148545, objectId=486c1485450b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486c1485450b, replyNumber=0, likeNumber=87, createdTime=2018-09-11, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486c1485450b, moduleTitle=美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486c1485450b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315764, encodeId=6dd91315e6450, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克将罕见病干细胞基因治疗技术转交给Orchard公司, objectType=article, longId=135323, objectId=a22a1353239f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a22a1353239f, replyNumber=0, likeNumber=81, createdTime=2018-04-15, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a22a1353239f, moduleTitle=葛兰素史克将罕见病干细胞基因治疗技术转交给Orchard公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a22a1353239f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315763, encodeId=7dda1315e638a, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克不再争夺辉瑞的消费者业务, objectType=article, longId=133321, objectId=9bcb133321e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bcb133321e8, replyNumber=0, likeNumber=63, createdTime=2018-03-25, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bcb133321e8, moduleTitle=葛兰素史克不再争夺辉瑞的消费者业务, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bcb133321e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315762, encodeId=0cd81315e62bc, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群, objectType=article, longId=132393, objectId=72881323939f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72881323939f, replyNumber=0, likeNumber=75, createdTime=2018-03-16, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72881323939f, moduleTitle=葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72881323939f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315761, encodeId=abee1315e616a, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克2017销售额增长3%, objectType=article, longId=129414, objectId=8017129414bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8017129414bd, replyNumber=0, likeNumber=69, createdTime=2018-02-10, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8017129414bd, moduleTitle=葛兰素史克2017销售额增长3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8017129414bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315760, encodeId=40751315e605e, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=强生退出了辉瑞消费保健品业务的竞选，为葛兰素史克（Reckitt）铺平了道路, objectType=article, longId=128059, objectId=6966128059e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6966128059e4, replyNumber=0, likeNumber=59, createdTime=2018-01-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6966128059e4, moduleTitle=强生退出了辉瑞消费保健品业务的竞选，为葛兰素史克（Reckitt）铺平了道路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6966128059e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315759, encodeId=32ce1315e59ab, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克宣布CHMP对Relvar Ellipta用于哮喘患者持有积极态度, objectType=article, longId=128058, objectId=47d212805800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47d212805800, replyNumber=0, likeNumber=52, createdTime=2018-01-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47d212805800, moduleTitle=葛兰素史克宣布CHMP对Relvar Ellipta用于哮喘患者持有积极态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47d212805800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315758, encodeId=74771315e58d7, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=欧盟专家组对葛兰素史克的带状疱疹疫苗Shingrix持积极态度, objectType=article, longId=128057, objectId=17d412805eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17d412805eaf, replyNumber=0, likeNumber=72, createdTime=2018-01-30, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17d412805eaf, moduleTitle=欧盟专家组对葛兰素史克的带状疱疹疫苗Shingrix持积极态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17d412805eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315757, encodeId=d1661315e577c, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, objectType=article, longId=123375, objectId=cf7e1233e57b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7e1233e57b, replyNumber=0, likeNumber=87, createdTime=2017-12-15, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7e1233e57b, moduleTitle=FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7e1233e57b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315756, encodeId=1d991315e56ed, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究, objectType=article, longId=96292, objectId=60ba962924a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60ba962924a, replyNumber=0, likeNumber=78, createdTime=2017-04-15, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60ba962924a, moduleTitle=葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60ba962924a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315755, encodeId=9c0b1315e5582, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=狼疮新药进展！葛兰素史克向美国和欧盟提交皮下注射剂型狼疮药Benlysta（每周一次）上市申请, objectType=article, longId=78353, objectId=b0cde8353c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cde8353c5, replyNumber=0, likeNumber=73, createdTime=2016-09-26, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cde8353c5, moduleTitle=狼疮新药进展！葛兰素史克向美国和欧盟提交皮下注射剂型狼疮药Benlysta（每周一次）上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cde8353c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315754, encodeId=f3601315e541d, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克剥离麻醉及血栓业务，进一步专注6大核心治疗领域, objectType=article, longId=77495, objectId=bad9e7495bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bad9e7495bd, replyNumber=0, likeNumber=75, createdTime=2016-09-16, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bad9e7495bd, moduleTitle=葛兰素史克剥离麻醉及血栓业务，进一步专注6大核心治疗领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bad9e7495bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315753, encodeId=b0041315e5350, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=风湿新药进展！葛兰素史克向欧盟提交IL-6单抗sirukumab上市申请, objectType=article, longId=77491, objectId=2db0e749190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db0e749190, replyNumber=0, likeNumber=94, createdTime=2016-09-16, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db0e749190, moduleTitle=风湿新药进展！葛兰素史克向欧盟提交IL-6单抗sirukumab上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db0e749190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315752, encodeId=00d01315e520e, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, objectType=article, longId=77042, objectId=be26e7042b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be26e7042b9, replyNumber=0, likeNumber=58, createdTime=2016-09-10, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be26e7042b9, moduleTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be26e7042b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315751, encodeId=8a471315e5174, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克将开发更加简便的艾滋病治疗药物, objectType=article, longId=76466, objectId=93dee6466a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93dee6466a7, replyNumber=0, likeNumber=31, createdTime=2016-09-03, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93dee6466a7, moduleTitle=葛兰素史克将开发更加简便的艾滋病治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93dee6466a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315750, encodeId=b7f61315e500f, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=喜讯！葛兰素史克新型狼疮药Benlysta获英国NICE批准, objectType=article, longId=71597, objectId=064ee159736, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=064ee159736, replyNumber=0, likeNumber=63, createdTime=2016-06-26, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=064ee159736, moduleTitle=喜讯！葛兰素史克新型狼疮药Benlysta获英国NICE批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=064ee159736)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315749, encodeId=9cb71315e4909, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID, objectType=article, longId=70013, objectId=d881e0013dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d881e0013dd, replyNumber=0, likeNumber=74, createdTime=2016-06-07, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d881e0013dd, moduleTitle=基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d881e0013dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315748, encodeId=1ca41315e48c0, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准, objectType=article, longId=70010, objectId=6a3fe001025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a3fe001025, replyNumber=0, likeNumber=91, createdTime=2016-06-07, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a3fe001025, moduleTitle=葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a3fe001025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315747, encodeId=10e41315e47c2, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克新专利政策将惠及不发达国家, objectType=article, longId=68150, objectId=83886815042, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83886815042, replyNumber=0, likeNumber=108, createdTime=2016-05-15, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83886815042, moduleTitle=葛兰素史克新专利政策将惠及不发达国家, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83886815042)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1315746, encodeId=78d01315e46c3, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, objectTitle=葛兰素史克红斑狼疮药物Benlysta获英国NICE批准, objectType=article, longId=68074, objectId=6359680e44f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6359680e44f, replyNumber=0, likeNumber=70, createdTime=2016-05-14, rootId=0, userName=sjq027, userId=d58a435, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6359680e44f, moduleTitle=葛兰素史克红斑狼疮药物Benlysta获英国NICE批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6359680e44f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

葛兰素史克

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#葛兰素史克#

美国FDA正式拒绝葛兰素史克的Nucala治疗COPD的申请

2018-09-11

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克将罕见病干细胞基因治疗技术转交给Orchard公司

2018-04-15

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克不再争夺辉瑞的消费者业务

2018-03-25

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群

2018-03-16

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克2017销售额增长3%

2018-02-10

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

强生退出了辉瑞消费保健品业务的竞选，为葛兰素史克（Reckitt）铺平了道路

2018-01-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克宣布CHMP对Relvar Ellipta用于哮喘患者持有积极态度

2018-01-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

欧盟专家组对葛兰素史克的带状疱疹疫苗Shingrix持积极态度

2018-01-30

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

FDA批准了葛兰素史克的用于治疗罕见自身免疫性疾病的生物制剂

2017-12-15

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究

2017-04-15

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

狼疮新药进展！葛兰素史克向美国和欧盟提交皮下注射剂型狼疮药Benlysta（每周一次）上市申请

2016-09-26

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克剥离麻醉及血栓业务，进一步专注6大核心治疗领域

2016-09-16

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

风湿新药进展！葛兰素史克向欧盟提交IL-6单抗sirukumab上市申请

2016-09-16

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler

2016-09-10

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克将开发更加简便的艾滋病治疗药物

2016-09-03

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

喜讯！葛兰素史克新型狼疮药Benlysta获英国NICE批准

2016-06-26

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

基因治疗新篇章！葛兰素史克干细胞基因疗法Strimvelis获欧盟批准治疗ADA-SCID

2016-06-07

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克用于治疗儿童免疫疾病的基因药获欧盟批准

2016-06-07

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克新专利政策将惠及不发达国家

2016-05-15

sjq027 (审核中...)

前往app查看评论内容

#葛兰素史克#

葛兰素史克红斑狼疮药物Benlysta获英国NICE批准

2016-05-14

科室
- - 订阅+
  - 更多科室
工具
服务